




Instance: composition-en-dc08afd9c59a04fa9fdda149a83f92c4
InstanceOf: CompositionUvEpi
Title: "Composition for tractocile Package Leaflet"
Description:  "Composition for tractocile Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpdc08afd9c59a04fa9fdda149a83f92c4)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tractocile"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Tractocile is and what it is used for  </li>
<li>What you need to know before you are given Tractocile  </li>
<li>How Tractocile will be given  </li>
<li>Possible side effects  </li>
<li>How to store Tractocile  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tractocile is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tractocile is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tractocile contains atosiban. Tractocile can be used to delay the premature birth of your baby. Tractocile is 
used in pregnant adult women, from week 24 to week 33 of the pregnancy.  </p>
<p>Tractocile works by making the contractions in your womb (uterus) less strong. It also makes the 
contractions happen less often. It does this by blocking the effect of a natural hormone in your body called 
 oxytocin  which causes your womb (uterus) to contract. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tractocile"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tractocile"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Tractocile 
- if you are less than 24 weeks pregnant. 
- if you are more than 33 weeks pregnant. 
- if your waters have broken (premature rupture of your membranes) and you have completed 30 weeks 
of your pregnancy or more. 
- if your unborn baby (foetus) has an abnormal heart rate. 
- if you have bleeding from your vagina and your doctor wants your unborn baby to be delivered 
straight away.<br />
- if you have something called  severe pre-eclampsia  and your doctor wants your unborn baby to be 
delivered straight away. Severe pre-eclampsia is when you have very high blood pressure, fluid 
retention and/or protein in your urine. 
- if you have something called  eclampsia  which is similar to  severe pre-eclampsia  but you would 
also have fits (convulsions). This will mean your unborn baby needs to be delivered straight away. 
- if your unborn baby has died. 
- if you have or could have an infection of your womb (uterus). 
- if your placenta is covering the birth canal. 
- if your placenta is detaching from the wall of your womb. 
- if you or your unborn baby have any other conditions where it would be dangerous to continue with 
your pregnancy. 
- if you are allergic to atosiban or any of the other ingredients of this medicine (listed in section 6).  </p>
<p>Do not use Tractocile if any of the above apply to you. If you are not sure, talk to your doctor, midwife or 
pharmacist before you are given Tractocile. 
Warnings and precautions<br />
Talk to your doctor, midwife or pharmacist before you are given Tractocile:</p>
<ul>
<li>if you think your waters might have broken (premature rupture of your membranes). </li>
<li>if you have kidney or liver problems. </li>
<li>if you are between 24 and 27 weeks pregnant. </li>
<li>if you are pregnant with more than one baby. </li>
<li>if your contractions start again, treatment with Tractocile can be repeated up to three more times. </li>
<li>if your unborn baby is small for the time of your pregnancy. </li>
<li>Your womb may be less able to contract after your baby has been born. This may cause bleeding. </li>
<li>if you are pregnant with more than one baby and/or are given medicines that can delay the birth of 
your baby, such as medicines used for high blood pressure. This may increase the risk of lung oedema 
(accumulation of fluid in the lungs). </li>
</ul>
<p>If any of the above apply to you (or you are not sure), talk to your doctor, midwife or pharmacist before you 
are given Tractocile. </p>
<p>Children and adolescents 
Tractocile has not been studied in pregnant women less than 18 years old. </p>
<p>Other medicines and Tractocile 
Tell your doctor, midwife or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant and breast-feeding an earlier child, you should stop breast-feeding while you are given 
Tractocile. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tractocile"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tractocile"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tractocile will be given to you in a hospital by a doctor, nurse or midwife. They will decide how much you 
need. They will also make sure the solution is clear and free from particles. </p>
<p>Tractocile will be given into a vein (intravenously) in three stages:</p>
<ul>
<li>The first injection of 6.75 mg in 0.9 ml will be slowly injected into your vein over one minute. </li>
<li>Then a continuous infusion (drip) will be given at a dose of 18 mg per hour for 3 hours. </li>
<li>Then another continuous infusion (drip) at a dose of 6 mg per hour will be given for up to 45 hours, or 
until your contractions have stopped. 
Treatment should last no longer than 48 hours in total. </li>
</ul>
<p>Further treatment with Tractocile can be used if your contractions start again. Treatment with Tractocile can 
be repeated up to three more times. </p>
<p>During treatment with Tractocile, your contractions and your unborn baby s heart rate may be monitored. </p>
<p>It is recommended that no more than three re-treatments should be used during a pregnancy. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The side effects seen in the mother are generally of a mild severity. There are no known side effects on the 
unborn or new-born baby. </p>
<p>The following side effects may happen with this medicine: 
Very common (affects more than 1 in 10 people) 
- feeling sick (nausea) </p>
<p>Common (affects less than 1 in 10 people) 
- headache 
- feeling dizzy 
- hot flushes<br />
- being sick (vomiting)<br />
- fast heartbeat 
- Low blood pressure. Signs may include feeling dizzy or light-headed.<br />
- A reaction at the site where the injection was given 
- high blood sugar </p>
<p>Uncommon (affects less than 1 in 100 people) 
- high temperature (fever) 
- difficulty sleeping (insomnia)<br />
- itching 
- rash </p>
<p>Rare (affects less than 1 in 1,000 people) 
- Your womb may be less able to contract after your baby has been born. This may cause bleeding. 
- allergic reactions </p>
<p>You may experience shortness of breath or lung oedema (accumulation of fluid in the lungs), particularly if 
you are pregnant with more than one baby and/or are given medicines that can delay the birth of your baby, 
such as medicines used for high blood pressure. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, midwife or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tractocile"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tractocile"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers 
to the last day of that month. </p>
<p>Store in a refrigerator (2 C - 8 C). </p>
<p>Store in the original package in order to protect from light. </p>
<p>Once the vial has been opened, the product must be used straight away. </p>
<p>Do not use this medicine if you notice particulate matter and discoloration prior to administration. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Tractocile contains<br />
- The active substance is atosiban. 
- Each vial of Tractocile 6.75 mg/0.9 ml solution for injection contains atosiban acetate equivalent to 
6.75 mg of atosiban in 0.9 ml. 
- The other ingredients are mannitol, hydrochloric acid and water for injections. 
What Tractocile looks like and contents of the pack 
Tractocile 6.75 mg/0.9 ml solution for injection is a clear, colourless solution without particles. One pack 
contains one vial containing 0.9 ml solution. </p>
<p>Marketing Authorisation Holder and Manufacturer 
Marketing Authorisation Holder: 
Ferring Pharmaceuticals A/S 
Amager Strandvej 2770 Kastrup 
Denmark 
Tel: +45 88 33 88 Manufacturer: 
Ferring GmbH 
Wittland D-24109 Kiel 
Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Ferring N.V.<br />
Tel/T l: +32 53 72 92 ferringnvsa@ferring.be  </p>
<p>Lietuva 
CentralPharma Communication UAB 
Tel: +370 5 243 0centralpharma@centralpharma.lt </p>
<p>: +359 2 807 5farmont@farmont.bg </p>
<p>Luxembourg/Luxemburg 
Ferring N.V. 
Belgique/Belgien 
Tel/T l: +32 53 72 92 ferringnvsa@ferring.be </p>
<p>esk  republika 
FerringPharmaceuticals CZ s.r.o. 
Tel: +420 234 701 cz1-info@ferring.com<br />
Magyarorsz g 
Ferring Magyarorsz g Gy gyszerkereskedelmi 
Kft. 
Tel: +36 1 236 3ferring@ferring.hu </p>
<p>Danmark 
Ferring L gemidler A/S 
Tlf: +45 88 16 88 Malta 
E.J. Busuttil Ltd.<br />
Tel: +356 21447info@ejbusuttil.com </p>
<p>Deutschland 
Ferring Arzneimittel GmbH<br />
Tel: +49 431 5852 0 
info-service@ferring.de </p>
<p>Nederland 
Ferring B.V. 
Tel: +31 235680infoNL@ferring.com </p>
<p>Eesti 
CentralPharma Communication O<br />
Tel: +372 601 5centralpharma@centralpharma.ee </p>
<p>Norge 
Ferring Legemidler AS 
Tlf: +47 22 02 08 mail@oslo.ferring.com </p>
<p>Ferring   <br />
 sterreich 
Ferring Arzneimittel Ges.m.b.H<br />
 : +30 210 68 43 Tel: +43 1 60 8office@ferring.at </p>
<p>Espa a 
Ferring S.A.U.<br />
Tel: +34 91 387 70 registros@ferring.com 
Polska 
Ferring Pharmaceuticals Poland Sp. z o.o. 
Tel: +48 22 246 06 PL0-Recepcja@ferring.com 
France 
Ferring S.A.S. 
T l: +33 1 49 08 67 information.medicale@ferring.com 
Portugal 
Ferring Portuguesa   Produtos Farmac uticos, 
Sociedade Unipessoal, Lda. 
Tel: +351 21 940 51 Hrvatska 
Clinres farmacija d.o.o. 
Tel: +385 1 2396 Rom nia 
Ferring Pharmaceuticals Romania SRL 
Tel: +40 356 113 Ireland 
Ferring Ireland Ltd.<br />
Tel: +353 1 4637EnquiriesIrelandMailbox@ferring.com </p>
<p>Slovenija 
SALUS, Veletrgovina, d.o.o.<br />
Tel: +386 1 5899 regulatory@salus.si  </p>
<p>sland 
Vistor hf. 
S mi: +354 535 70 Slovensk  republika 
Ferring Slovakia s.r.o. 
Tel: +421 2 54 416 SK0-Recepcia@ferring.com </p>
<p>Italia 
Ferring S.p.A. 
Tel: +39 02 640 00 Suomi/Finland 
Ferring L kkeet Oy<br />
Puh/Tel: +358 207 401 info@ferring.fi </p>
<p>A. Potamitis Medicare Ltd 
 : +357 22583a.potamitismedicare@cytanet.com.cy </p>
<p>Sverige 
Ferring L kemedel AB 
Tel: +46 40 691 69 info@ferring.se 
Latvija 
CentralPharma Communication SIA 
T lr: +371 674 50centralpharma@centralpharma.lv 
United Kingdom (Northern Ireland) 
Ferring Ireland Ltd.<br />
Tel: +353 1 4637EnquiriesIrelandMailbox@ferring.com </p>
<p>This leaflet was last revised in . </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-dc08afd9c59a04fa9fdda149a83f92c4
InstanceOf: CompositionUvEpi
Title: "Composition for tractocile Package Leaflet"
Description:  "Composition for tractocile Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpdc08afd9c59a04fa9fdda149a83f92c4)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tractocile"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du får Tractocile<br />
3. Sådan får du Tractocile<br />
4. Bivirkninger<br />
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tractocile is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tractocile is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tractocile indeholder atosiban. Tractocile kan bruges til at modvirke for tidlig fødsel af dit barn. 
Tractocile anvendes til gravide voksne kvinder fra uge 24 til uge 33 i graviditeten. </p>
<p>Tractocile virker ved at gøre sammentrækningerne i livmoderen (uterus) mindre kraftige. Desuden 
nedsættes hyppigheden af sammentrækningerne. Det sker, fordi Tractocile forhindrer virkningen af det 
naturlige hormon i din krop kaldet "oxytocin", som forårsager sammentrækninger i livmoderen.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tractocile"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tractocile"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må ikke få Tractocile 
- hvis din graviditet har varet under 24 uger 
- hvis din graviditet har varet over 33 uger 
- hvis dit vand er gået (ved for tidlig brist på fosterhinderne) og dette sker efter 30 ugers 
graviditet eller mere 
- hvis fosterets hjertefrekvens er unormal<br />
- hvis du oplever blødning fra livmoderen, der kræver øjeblikkelig igangsættelse af fødslen 
- hvis du har alvorlig svangerskabsforgiftning (præeklampsi) (højt blodtryk, tilbageholdelse af 
væske og/eller protein i urinen), der kræver øjeblikkelig igangsættelse af fødslen 
- hvis du har graviditetskramper eller fødselskramper (eklampsi) (kramper sammen med 
svangerskabsforgiftning), som kræver øjeblikkelig igangsættelse af fødslen 
- hvis fosteret ikke er levende 
- ved mistanke om infektion i livmoderen 
- hvis moderkagen dækker fødselsvejen 
- hvis moderkagen er ved at løsne sig<br />
- ved andre tilstande, hvor en fortsættelse af graviditeten anses for at være farlig for dig eller det 
ufødte barn. 
- hvis du er allergisk over for atosiban eller et af de øvrige indholdsstoffer i Tractocile (angivet i 
punkt 6) </p>
<p>Du må ikke få Tractocile hvis noget af det ovenstående passer på dig. Hvis du er usikker, så spørg din 
læge, jordemoder eller på apoteket, før du får Tractocile. </p>
<p>Advarsler og forsigtighedsregler: 
Kontakt læge, jordemoder eller apotekspersonalet før du får Tractocile 
- hvis du tror, fostervandet er gået (for tidlig brist på fosterhinder) 
- hvis du har nyre- eller leverproblemer 
- hvis du er mellem 24 og 27 uger henne i graviditeten 
- hvis du er gravid med flere fostre<br />
- hvis sammentrækningerne af livmoderen kommer igen kan behandling med Tractocile gentages 
op til tre gange mere 
- hvis fosteret er for lille i forhold til graviditetens varighed<br />
- når barnet er født, kan livmodernes evne til at trække sig sammen være nedsat. Dette kan give 
blødning. 
- hvis du er gravid med flere fostre (tvillinger, trillinger etc.) og/eller tager medicin, der kan 
forsinke fødslen, såsom lægemidler, der bruges mod for højt blodtryk. Det kan øge risikoen for 
lungeødem (væskeansamling i lungerne).  </p>
<p>Hvis noget af det ovenstående passer på dig eller hvis du er usikker, så spørg din læge, jordemoder 
eller på apoteket, før du får Tractocile. </p>
<p>Børn og teenagere 
Tractocile er ikke undersøgt hos gravide kvinder under 18 år. </p>
<p>Brug af anden medicin sammen med Tractocile 
Fortæl det altid til lægen, jordemoderen eller på apoteket hvis du bruger anden medicin eller har gjort 
det for nylig.  </p>
<p>Graviditet og amning 
Hvis du er gravid, men stadig ammer et ældre barn, skal du stoppe amningen, imens du får Tractocile </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tractocile"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tractocile"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du får Tractocile på et hospital af en læge, sygeplejerske eller jordemoder. De vil vurdere hvor meget 
du har brug for. De vil også sikre sig, at injektionsvæsken er klar og fri for partikler.  </p>
<p>Tractocile indsprøjtes i en vene (intravenøst) i tre trin:</p>
<ul>
<li>en indledende intravenøs injektion på 6,75 mg i 0,9 ml injiceres langsomt i en vene over 1 minut. </li>
<li>en opfølgende infusion med en styrke på 18 mg/time gives i 3 timer. </li>
<li>en opfølgende infusion med en styrke på 6 mg/time gives i op til 45 timer, eller indtil 
sammentrækningerne af livmoderen er stilnet af. 
Behandlingen må højst vare i 48 timer.  </li>
</ul>
<p>Yderligere behandlingscykler med Tractocile kan bruges hvis sammentrækningerne af livmoderen 
opstår igen. Behandlingen med Tractocile kan gentages op til tre gange mere. </p>
<p>Under behandling med Tractocile, vil dine sammentrækninger og dit ufødte barns hjertefrekvens 
sandsynligvis blive fulgt.  </p>
<p>Det frarådes at foretage mere end tre genbehandlinger under en graviditet. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>De bivirkninger, som er set hos moderen, var generelt ikke af alvorlig karakter. Der kendes ingen 
bivirkninger for fosteret eller det nyfødte barn. </p>
<p>Følgende bivirkninger kan forekomme ved brug af denne medicin: </p>
<p>Meget almindelig (forekommer hos mere end 1 ud af 10 brugere) 
- kvalme </p>
<p>Almindelig (forekommer hos mindre end 1 ud af 10 brugere) 
- hovedpine 
- svimmelhed 
- hedeture 
- opkastning 
- hurtig hjerterytme 
- lavt blodtryk, hvor et af symptomerne kan være svimmelhed 
- reaktion på injektionsstedet 
- højt blodsukker </p>
<p>Ikke almindelig (forekommer hos mindre end 1 ud af 100 brugere) 
- feber 
- søvnløshed 
- kløe 
- udslæt </p>
<p>Sjælden (forekommer hos mindre end 1 ud af 1.000 brugere) 
- når barnet er født, kan livmodernes evne til at trække sig sammen være nedsat. Dette kan give 
blødning. 
- allergiske reaktioner </p>
<p>Du kan opleve åndenød eller lungeødem (væskeansamling i lungerne), især hvis du er gravid med flere 
fostre (tvillinger, trillinger etc.) og/eller får andre lægemidler, der kan forsinke fødslen, såsom 
lægemidler mod højt blodtryk. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Sundhedsstyrelsen via det nationale rapporteringssystem anført 
i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tractocile"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tractocile"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar dette lægemiddel utilgængeligt for børn. </p>
<p>Brug ikke dette lægemiddel efter udløbsdatoen, der er angivet på etiketten efter EXP. Udløbsdatoen er 
den sidste dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2 °C - 8 °C). </p>
<p>Opbevares i den originale yderpakning, for at beskytte mod lys. </p>
<p>Opløsninger til intravenøs infusion skal anvendes indenfor 24 timer efter fremstillingen. </p>
<p>Anvend ikke dette lægemiddel, hvis der er tegn på partikler eller misfarvning inden indgivelsen. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tractocile indeholder:</p>
<ul>
<li>Aktivt stof: atosiban </li>
<li>Hvert hætteglas med Tractocile 37,5 mg/5 ml koncentrat til infusionsvæske, opløsning 
indeholder atosibanacetate svarende til 37,5 mg atosiban i 5 ml </li>
<li>De øvrige indholdsstoffer er mannitol, saltsyre og vand til injektionsvæsker </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Tractocile 37,5 mg/5 ml koncentrat til infusionsvæske, opløsning er en klar, farveløs opløsning uden 
partikler. En æske indeholder et hætteglas indeholdende 5 ml opløsning. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>Indehaver af markedsføringstilladelsen: 
Ferring Pharmaceuticals A/S 
Amager Strandvej 2770 Kastrup 
Danmark 
Tlf: +45 88 33 88<br />
Fremstiller: 
Ferring GmbH 
Wittland D-24109 Kiel 
Tyskland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen. </p>
<p>België/Belgique/Belgien 
Ferring N.V.<br />
Tel/Tél: +32 53 72 92 ferringnvsa@ferring.be<br />
Lietuva 
CentralPharma Communication UAB 
Tel.: +370 5 243 0centralpharma@centralpharma.lt </p>
<p>България 
Фармонт ЕООДТел: +359 2 807 5farmont@farmont.bg 
Luxembourg/Luxemburg 
Ferring N.V. 
Belgique/Belgien 
Tel/Tél : +32 53 72 92 ferringnvsa@ferring.be </p>
<p>Česká republika 
Ferring Pharmaceuticals CZ s.r.o. 
Tel: +420 234 701 cz1-info@ferring.com<br />
Magyarország 
Ferring Magyarország 
Gyógyszerkereskedelmi Kft. 
Tel: +36 1 236 3ferring@ferring.hu </p>
<p>Danmark 
Ferring Lægemidler A/S 
Tlf: +45 88 16 88  </p>
<p>Malta 
E.J. Busuttil Ltd.<br />
Tel: +356 21447184<br />
info@ejbusuttil.com </p>
<p>Deutschland 
Ferring Arzneimittel GmbH<br />
Tel: +49 431 5852 0 
Nederland 
Ferring B.V. 
Tel: +31 235680info-service@ferring.de </p>
<p>infoNL@ferring.com </p>
<p>Eesti 
CentralPharma Communication OÜ 
Tel.: +372 601 5centralpharma@centralpharma.ee </p>
<p>Norge 
Ferring Legemidler AS 
Tlf: +47 22 02 08 mail@oslo.ferring.com 
Ελλάδα 
Ferring Ελλάς ΜΕΠΕ 
Τηλ: +30 210 68 43 Österreich 
Ferring Arzneimittel Ges.m.b.H<br />
Tel: +43 1 60 8office@ferring.at </p>
<p>España 
Ferring S.A.U.<br />
Tel: +34  91 387 70 registros@ferring.com 
Polska 
Ferring Pharmaceuticals Poland Sp. z o.o. 
Tel: +48 22 246 06 PL0-Recepcja@ferring.com </p>
<p>France 
Ferring S.A.S. 
Tél: +33 1 49 08  67 information.medicale@ferring.com 
Portugal 
Ferring Portuguesa - Produtos 
Farmacêuticos, Sociedade Unipessoal, Lda. 
Tel: +351 21 940 51<br />
Hrvatska 
Clinres farmacija d.o.o. 
Tel: +385 1 2396 România 
Ferring Pharmaceuticals Romania SRL 
Tel: +40 356 113<br />
Ireland 
Ferring Ireland Ltd.<br />
Tel: +353 1 4637EnquiriesIrelandMailbox@ferring.com 
Slovenija 
SALUS, Veletrgovina, d.o.o.<br />
Tel: +386 1 5899 179<br />
regulatory@salus.si 
Ísland 
Vistor hf. 
Sími: +354 535 70 Slovenská republika 
Ferring Slovakia s.r.o. 
Tel: +421 2 54 416 SK0-Recepcia@ferring.com </p>
<p>Italia 
Ferring S.p.A. 
Tel: +39 02 640 00 Suomi/Finland 
Ferring Lääkkeet Oy<br />
Puh/Tel: +358 207 401 info@ferring.fi </p>
<p>Κύπρος 
A. Potamitis Medicare Ltd 
Τηλ: +357 22583a.potamitismedicare@cytanet.com.cy </p>
<p>Sverige 
Ferring Läkemedel AB 
Tel: +46 40 691 69 info@ferring.se 
Latvija 
CentralPharma Communication SIA 
Tālr: +371 6 674 50centralpharma@centralpharma.lv </p>
<p>United Kingdom (Northern Ireland) 
Ferring Ireland Ltd.<br />
Tel: +353 1 4637EnquiriesIrelandMailbox@ferring.com </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu </p>
<hr />
<p>Følgende oplysninger er tiltænkt læger og sundhedspersonale (se også punkt 3). </p>
<p>Instruktioner for brug  </p>
<p>Inden Tractocile anvendes, skal injektionsvæsken undersøges visuelt. Den skal være klar og fri for 
partikler.  </p>
<p>Tractocile gives intravenøst i tre successive stadier:</p>
<ul>
<li>Den indledende intravenøse injektion på 6,75 mg i 0,9 ml injiceres langsomt i en vene over 1 
minut. </li>
<li>En uafbrudt infusion på 24 ml/time gives i 3 timer. </li>
<li>En uafbrudt infusion på 8 ml/time gives i op til 45 timer, eller indtil livmoderens 
sammentrækninger er aftaget. </li>
</ul>
<p>Behandlingen må højst vare 48 timer i alt. Yderligere behandlingscykler med Tractocile kan bruges, 
hvis sammentrækningerne af livmoderen opstår igen. Det tilrådes ikke at foretage mere end tre 
genbehandlinger under en graviditet. </p>
<p>Tilberedning af intravenøs infusion 
Den intravenøse infusion tilberedes ved at fortynde Tractocile 37,5 mg/5 ml koncentrat til 
infusionsvæske, opløsning i natriumchloridopløsning 9 mg/ml (0,9%), Ringers lactatopløsning eller 
5% w/v glucoseopløsning. Dette gøres ved at udtage 10 ml opløsning fra en 100 ml infusionspose og 
erstatte dem med 10 ml Tractocile 37,5 mg/5 ml koncentrat til infusionsvæske, opløsning fra to 5 ml 
hætteglas for at opnå en koncentration på 75 mg atosiban i 100 ml. Såfremt der anvendes en 
infusionspose med et andet volumen skal en forholdsmæssig beregning udføres for denne. </p>
<p>Tractocile bør ikke blandes med andre lægemidler i infusionsposen. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-dc08afd9c59a04fa9fdda149a83f92c4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tractocile Package Leaflet for language en"
Description: "ePI document Bundle for tractocile Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-dc08afd9c59a04fa9fdda149a83f92c4"
* entry[0].resource = composition-en-dc08afd9c59a04fa9fdda149a83f92c4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpdc08afd9c59a04fa9fdda149a83f92c4"
* entry[=].resource = mpdc08afd9c59a04fa9fdda149a83f92c4
                            
                    
Instance: bundlepackageleaflet-da-dc08afd9c59a04fa9fdda149a83f92c4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tractocile Package Leaflet for language da"
Description: "ePI document Bundle for tractocile Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-dc08afd9c59a04fa9fdda149a83f92c4"
* entry[0].resource = composition-da-dc08afd9c59a04fa9fdda149a83f92c4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpdc08afd9c59a04fa9fdda149a83f92c4"
* entry[=].resource = mpdc08afd9c59a04fa9fdda149a83f92c4
                            
                    



Instance: mpdc08afd9c59a04fa9fdda149a83f92c4
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Tractocile 6.75 mg/0.9 ml solution for injection"
Description: "Tractocile 6.75 mg/0.9 ml solution for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/99/124/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Tractocile 6.75 mg/0.9 ml solution for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: dc08afd9c59a04fa9fdda149a83f92c4ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "tractocile"

* status = #current
* mode = #working

* title = "List of all ePIs associated with tractocile"

* subject = Reference(mpdc08afd9c59a04fa9fdda149a83f92c4)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#tractocile "tractocile"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-dc08afd9c59a04fa9fdda149a83f92c4) // tractocile en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-dc08afd9c59a04fa9fdda149a83f92c4) // tractocile da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-dc08afd9c59a04fa9fdda149a83f92c4
InstanceOf: List

* insert dc08afd9c59a04fa9fdda149a83f92c4ListRuleset
    